Search results: (10000)
News When Teriflunomide and Interferon Join Forces
Progressive multifocal leukoencephalopathy is a nightmare for all doctors prescribing disease-modifying therapies for multiple sclerosis. How Swiss colleagues dealt with this situation is illuminated by the following case study.
News Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple pharmacokinetic protocol for patients with hemophilia A.
News Even in Severe Cases of HAE, Individualized Treatment is Crucial – Case Study
As part of the case seminar from the HAExpert series, held on December 1, 2021, which specifically focused on the treatment of hereditary angioedema (HAE) in specific patients, Dr. Roman Hakl from the Institute of Clinical Immunology and Allergology at MU Faculty of Medicine and St. Anne's University Hospital in Brno presented the case of a now 34-year-old woman with HAE and obesity (BMI 37 kg/m2), who additionally has a positive family history – the disease was also diagnosed in her mother, sister, and son.
News How and How the Czech National Hemophilia Program Benefits Professionals and Patients
The Czech National Hemophilia Program (ČNHP) has been an interdisciplinary initiative for many years, coordinating specialized care for both pediatric and adult patients with hemophilia and other congenital bleeding disorders in the Czech Republic. It was established on the platform of collaboration among experts from hematology centers that deal with this issue and is guided by the ČNHP Declaration, which is published on the association's website (see www.cnhp.cz).
News Does gliflozin treatment for heart failure have greater benefits in diabetics?
Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by several molecules including empagliflozin. The EMPEROR-Reduced study monitored the impact of empagliflozin administration in individuals with heart failure with reduced ejection fraction (HFrEF) and compared the results in patients with and without diabetes.
News How many heart failure patients do not take adequate doses of beta-blockers even though they could?
A British study published last year investigated the proportion of heart failure patients with reduced ejection fraction (HFrEF) who do not take an adequate dose of beta-blockers (BB), despite having no contraindications to their use. The authors analyzed the mortality of these patients over 7.6 years and looked for factors associated with the prescription of suboptimal BB doses.
News Does the choice of therapy for primary hypertension in patients with COVID-19 affect the severity of the disease?
The effect of two commonly used antihypertensives was evaluated in a randomized clinical trial in patients with primary hypertension and COVID-19.
News Is it beneficial to combine etanercept and methotrexate in the treatment of psoriatic arthritis?
The study presented below by Canadian, American, and British authors focused on comparing the efficacy of monotherapy with methotrexate, etanercept, and their combination in patients with psoriatic arthritis.
News Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the group of factors with an extended half-life. The authors of a systematic review and meta-analysis published last year assessed its efficacy and safety in patients previously treated for hemophilia A.
News Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of the work presented below discuss the significance of prophylactic administration of factor VIII coagulation concentrates, specifically concerning neurological complications related to bleeding.
News Teriflunomide under the microscope in studies and practice
Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and individual studies?
News Reduction of Mortality in Patients After Abdominal Surgery in Critical Condition Thanks to Early Supplemental Parenteral Nutrition
Ensuring adequate nutrition is an important part of therapy for critically ill patients to achieve better clinical outcomes in terms of both survival and recovery speed. The preferred option is enteral nutrition (EN), which, however, cannot be provided for many reasons to patients after acute abdominal surgery. The results of studies assessing the efficacy of parenteral nutrition (PN) in this specific group of patients are inconsistent. The purpose of the study recently published in Clinical Nutrition was therefore to evaluate the effect of early supplementary parenteral nutrition in critically ill patients after acute abdominal surgery.
News Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients
Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody against IL-17A and IL-17F, bimekizumab, in patients with plaque psoriasis using a prefilled syringe or autoinjector.
News Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?
A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the results of the KCCQ-23 questionnaire, which assesses the patient's health status from their perspective. Its goal was to verify whether the benefit of empagliflozin added to the treatment of heart failure with reduced left ventricular ejection fraction (HFrEF) depends on the initial health status and how it subsequently affects the health status of these patients over 1 year.
News Comparison of Dabigatran and Vitamin K Antagonists in Patients with Atrial Fibrillation in Real-World Practice
The final 3-year results of the GLORIA-AF study conducted in real-world practice with patients newly diagnosed with atrial fibrillation show a lower incidence of major bleeding and lower overall mortality with comparably effective prevention of cerebrovascular accidents and myocardial infarction when administering dabigatran compared to vitamin K antagonists (VKAs).
News Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure or death from cardiovascular (CV) causes in the EMPEROR-Reduced study in patients with adequately treated heart failure with reduced left ventricular ejection fraction (HFrEF) compared to placebo, regardless of whether the patients had diabetes. A post hoc analysis of this study focused on another important question: how does the benefit of adding empagliflozin interact with the standard disease-modifying therapy for heart failure?
News Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A
The famous slogan of neurologists in connection with strokes – 'Time is brain!' – can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial role in the prognosis of patients with AHA – delayed diagnosis is associated with longer administration of hemostatic treatment, higher risk of relapses, and mortality.
News Current Challenges in Diagnosing Progressive Fibrotic Interstitial Lung Diseases
A subset of patients with interstitial lung diseases exhibits a progressive fibrotic phenotype associated with a deterioration in quality of life and increased mortality. Early diagnosis and adequate therapy could improve their prognosis, but currently, there are numerous problems and challenges.
News Risks Associated with Higher Residual Concentrations of Dabigatran in Seniors and Their Prevalence
Dabigatran is a direct thrombin inhibitor indicated for patients across the age spectrum. The benefit-risk assessment of anticoagulation is individual and depends on many factors. A Dutch observational pilot study examined residual concentrations of dabigatran in seniors of different ages with atrial fibrillation to clarify the relationship between study results and clinical practice.
News Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib
Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has demonstrated efficacy in patients with ALK+ non-small cell lung cancer (NSCLC) who are refractory to crizotinib as well as in ALK+ NSCLC not previously treated with an ALK inhibitor. Post hoc analysis of the ALTA-1L trial, presented as a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting, addresses whether the maximum reduction in target lesions of ALK+ NSCLC treated with brigatinib or crizotinib correlates with overall survival (OS) and progression-free survival (PFS).
News Frequency of Participation in Sports Activities and the Risk of Injury in Children with Hemophilia
In children with hemophilia, numerous positive effects of physical activity on their health have been described. However, due to concerns about injuries and joint bleeding, young hemophiliacs may often be limited in real participation in sports life. Results from published studies, however, indicate that with proper therapy, the frequency of injuries is similar to that of the general population.
News Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.
News The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
We summarize the results of a clinical study on the effect of probiotics containing Limosilactobacillus reuteri on the improvement of gingivitis in patients with diabetes. It has been proven that the supplementary administration of L. reuteri statistically significantly improves gum health and helps to suppress gingival inflammation.
News Invitation to ZEPOSIA STAND ALONE MEETING
On behalf of Bristol Myers Squibb, we warmly invite you to the Zeposia Stand Alone Meeting, which will take place on March 22, 2023, at 5 PM at the EA Hotel Tereziánský dvůr in Hradec Králové.
News Technology as an Aid in Home Oral Care
Good oral hygiene is a prerequisite for good health, both in the mouth area and in terms of overall condition. To make it more effective and easier, it is now possible to use technologically advanced tools that allow users to achieve and maintain high hygiene standards in regular daily care.